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ABSTRACT
Accuracy of protein synthesis is enabled by the
selection of amino acids for tRNA charging by
aminoacyl-tRNA synthetases (ARSs), and further
enhanced by the proofreading functions of some
of these enzymes for eliminating tRNAs mis-
charged with noncognate amino acids. Mouse mod-
els of editing-defective cytoplasmic alanyl-tRNA syn-
thetase (AlaRS) have previously demonstrated the
importance of proofreading for cytoplasmic pro-
tein synthesis, with embryonic lethal and progres-
sive neurodegeneration phenotypes. Mammalian mi-
tochondria import their own set of nuclear-encoded
ARSs for translating critical polypeptides of the ox-
idative phosphorylation system, but the importance
of editing by the mitochondrial ARSs for mitochon-
drial proteostasis has not been known. We demon-
strate here that the human mitochondrial AlaRS is ca-
pable of editing mischarged tRNAs in vitro, and that
loss of the proofreading activity causes embryonic
lethality in mice. These results indicate that tRNA
proofreading is essential in mammalian mitochon-
dria, and cannot be overcome by other quality control
mechanisms.
INTRODUCTION
Functionality of mitochondria is central for maintaining
cellular homeostasis through their involvement in multi-
ple biosynthetic pathways and in ATP production by ox-
idative phosphorylation. Protein synthesis machineries in
two cellular compartments, cytoplasm and mitochondria,
are needed to fulfill these functions. The mitochondrial pro-
teome is mostly synthesized by cytosolic ribosomes and im-
ported into mitochondria. However, 13 essential subunits
of the mitochondrial respiratory chain complexes are syn-
thesized by dedicated mitoribosomes within the organelle
(1,2). These 13 polypeptides, as well as the mitochondrial
tRNAs and rRNAs, are encoded by mitochondrial DNA
(mtDNA). On the contrary, all protein components of the
mitochondrial translation machinery such as the mitoribo-
somal proteins and the 19 mitochondrial aminoacyl-tRNA
synthetases (mtARSs) are nuclear-encoded proteins, which
are imported into mitochondria (3,4).
Several mechanisms that control mitochondrial protein
integrity have been identified. These include intraorganel-
lar chaperone and protease systems (5), mitochondrial-
derived vesicle pathways (6) and mitophagy, the selective
autophagy of damaged mitochondria for clearing entire
dysfunctional organelles (7). Furthermore, quality control
mechanisms exist for proteins residing in different mito-
chondrial compartments as was recently demonstrated for
mitochondrial membrane proteins (8). Impaired mitochon-
drial protein quality control is associated with multiple
pathologies, especially those affecting the central nervous
system (9), and also contributes to organismal stress resis-
tance and even longevity through induction of cellular stress
responses such as the mitochondrial unfolded protein re-
sponse (10,11).
The fidelity of protein synthesis itself markedly con-
tributes to protein quality. It is mediated by the aminoacyl-
tRNA synthetases (ARSs) that establish the genetic code by
charging tRNAswith their cognate amino acids. tRNA syn-
thetases recognize their cognate amino acids by fitting them
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in a defined pocket of the aminoacylation site. However,
some synthetases are unable to discriminate against highly
similar amino acids, and mischarge tRNAs with noncog-
nate amino acids. To avoidmistranslation, some synthetases
have an editing activity for hydrolyzing the mischarged or
misactivated amino acid. The editing functions ofARSs can
occur pre- or post-transfer on cognate tRNAs. Pre-transfer
editing is thought to take place at the synthetic active site
when the non-cognate amino acid is activated by ATP, but
not yet transferred to the tRNA, whereas post-transfer edit-
ing is for noncognate amino acids that are already attached
to the tRNA. Synthetases with post-transfer editing activ-
ity have spatially separated editing domains with active sites
that can recognize only noncognate amino acids of misacy-
lated tRNAs (12). The post-transfer editing can be either
cis- or trans-editing, depending onwhether it occurs directly
after the tRNA charging or after the release of the mis-
charged tRNA from the synthetase, respectively.
The in vivo significance of avoiding mistranslation is
demonstrated by the spontaneous sti mouse mutation in
the cytoplasmic alanyl-tRNA synthetase (AlaRS), caus-
ing a cerebellar ataxia with progressive degeneration of
Purkinje cells (13). AlaRSs are the most conserved tRNA
synthetases, consisting of an N-terminal aminoacylation
domain, editing domain, and a C-terminal domain (14).
AlaRSs misactivate glycine and serine, of which serine mis-
incorporation is considered to be universally toxic (15). In
E. coli, a severe editing mutation of AlaRS prevents cell
growth in high concentrations of glycine and serine (16) and
in mice the equivalent editing mutant is embryonic lethal
(17). The sti mutation causes only a mild reduction in dea-
cylation of Ser-tRNAAla, which then leads to the slowly
progressive neurodegeneration with increased levels of mis-
folded proteins and activated unfolded protein response.
Defective proofreading at the level of mtDNA replica-
tion causes a premature aging phenotype inmice (18). How-
ever, the importance of mischarged tRNA editing in mam-
malian mitochondria has not been demonstrated. In fact,
severalmtARSs have been reported to lack editing function.
For example, editing activity was lost during the evolution
of mitochondrial phenylalanyl-tRNA synthetases (19,20),
and the editing active site of human mitochondrial leucyl-
tRNA synthetase is not operational (21). Therefore it was
suggested that mitochondrial protein synthesis is inher-
ently less accurate or that its protein quality control is fo-
cused on another step (20). Recently, however, the human
mitochondrial threonyl-tRNA synthetase (mtThrRS) was
shown to use post-transfer editing to clear cognate tRNAs
mischarged with serine in vitro (22).
We demonstrate here that mammalian mitochondrial
alanyl-tRNA synthetase (mtAlaRS), which has a highly
conserved editing domain (23,24), is capable of editing mis-
charged Ser-tRNAAla in vitro. Furthermore, as an effort to
investigate mitochondrial mistranslation in vivo, we have
generated editing-deficient mtAlaRS mice, bearing either a
mild or a severe mtAlaRS editing mutation, and demon-
strate that editing of mischarged tRNAs by alanyl-tRNA
synthetase is an essential protein quality controlmechanism
in mammalian mitochondria.
MATERIALS AND METHODS
Cloning and gene expression of human mtAlaRS
HumanAARS2 cDNAwas cloned into pBabe-puro expres-
sion vector using EcoRI and SalI restriction sites. Point
mutants for amino acid changes C749A or V760E in hu-
man AARS2 were introduced by PCR-based site-directed
mutagenesis with Phusion high-fidelity DNA polymerase
(Thermo Fisher Scientific). The DNA fragments encoding
mature wild type hmtAlaRS from Ser26-Leu985 (25), or with
mutations C749A or V760E were cloned betweenNdeI and
XhoI of pET30a. All primer sequences are available on re-
quest. Escherichia coli BL21 (DE3) cells were transformed
with the plasmids to overproduce wild type hmtAlaRS, or
the C749A and V760E mutants with a C-terminal His6 tag.
The gene expression was induced with a final concentration
of 100 M IPTG at 22◦C for 10 h. The first-step affinity
chromatography on Ni-NTA Superflow was performed ac-
cording to the method described previously (26). The pro-
tein was then purified by gel filtration chromatography with
a SuperdexTM 200 column with the running buffer 50 mM
Tris–HCl (pH 8.0) and 50 mM NaCl. The fractions corre-
sponding to hmtAlaRS were collected.
Transcription of human mitochondrial tRNAAla
(hmtRNAAla)
The sequence of hmtRNAAla is 5′-AAGGGCTTAGC
TTAATTAAAGTGGCTGATTTGCGTTCA GTTGA
TGCAGAGTGGGGTTTTGCAGTCCTTACCA-3′.
We inserted a hammerhead ribozyme sequence
(GGGAGACCTTCTGATGAGTCCGTGAGGACGAA
ACGGTACCCGGTACCGTC) between T7 promoter and
the hmtRNAAla gene to facilitate in vitro T7 transcription
(27). Six complementary and overlapping oligonucleotides
encoding T7 promotor, the hammerhead ribozyme se-
quence and the hmtRNAAla gene, and its complementary
chain were chemically synthesized by Biosune (Shanghai,
China). The fragments were then cloned between the
PstI and EcoRI sites of pTrc99b with an N-terminal T7
promoter. Detailed T7 in vitro run-off transcription of
hmtRNAAla was performed according to the method
described previously (28), with an additional incubation
of the transcription reaction at 60◦C for 1 h after the
template was digested for self-cleavage of the ribozyme.
32P-labeling of hmtRNAAla by E. coli CCA-adding enzyme
was performed as described previously (29).
ATP-PPi exchange assay
Kinetics of amino acid activation of hmtAlaRS, C749A
and V760E were determined by ATP-PPi exchange reac-
tion in a reaction buffer containing 50 mM Tris–HCl (pH
8.0), 20 mM KCl, 10 mMMgCl2, 2 mM DTT, 4 mM ATP,
(0.5–40) mM Ala, or (100–1500) mM Ser, 2 mM tetra-
sodium [32P]pyrophosphate and 200 nM enzyme at 37◦C.
A 9 l aliquot of reaction mixture was removed into 200
l quenching solution (2% activated charcoal, 3.5%HClO4,
and 50 mM tetrasodium pyrophosphate) andmixed on vor-
tex. The solution was filtered through Whatman GF/C fil-
ter, followed by washing with 20 ml 10 mM tetrasodium
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pyrophosphate solution and 10 ml 100% ethanol. The fil-
ters were dried and [32P]ATP was counted by scintillation
counter (Beckman Coulter).
In vitro aminoacylation assay
In vitro aminoacylation assay was performed in a reaction
buffer containing 50 mM Tris–HCl (pH 8.0), 20 mM KCl,
10 mMMgCl2, 2 mM DTT, 4 mM ATP, 100 M [14C]Ala,
5 MhmtRNAAla and 400 nM hmtAlaRS and its two vari-
ants at 37◦C. Aliquots of 9 l reaction solution were re-
moved at specific time-points and quenched on Whatman
filter pads, equilibrated with 5% trichloroacetic acid (TCA).
The pads were washed three times for 15 min each with cold
5% TCA and then three times for 10 min each with 100%
ethanol. The pads were dried by a heat lamp. The radioac-
tivities of the precipitates were quantified by scintillation
counter (Beckman Coulter).
In vitro mis-aminoacylation
In vitro mis-ammnoacylation assay was performed in a re-
action buffer containing 50 mMTris–HCl (pH 8.0), 20 mM
KCl, 10 mM MgCl2, 2 mM DTT, 4 mM ATP, 454 M
[14C]Ser, 5 M hmtRNAAla and 1 M hmtAlaRS and its
two variants at 37◦C. The processing and the quantification
were performed as described above.
Post-transfer editing assay
Preparation of Ser-[32P]hmtRNAAla was carried out with
editing-deficient C749A in a reaction mixture, which was
similar to that used for mis-aminoacylation except that un-
labeled Ser and [32P]hmtRNAAla were added. Post-transfer
editing assay was performed in a reaction buffer contain-
ing 60 mM Tris–HCl (pH 7.5), 10 mM MgCl2, 2 M Ser-
[32P]hmtRNAAla, 500 nM hmtAlaRS and its two variants
at 37◦C. Processing of samples was performed as described
previously (22). Nuclease S1-generated Ser-[32P]AMP (re-
flecting Ser-[32P]hmtRNAAla) and [32P]AMP (reflecting free
[32P]hmtRNAAla) were separated by thin layer chromatog-
raphy (TLC). A control reaction represented the sponta-
neous hydrolysis of Ser-[32P]hmtRNAAla without the addi-
tion of enzyme.
Structure analysis of mtAlaRS editing domain
The editing core of mouse mtAlaRS containing editing ac-
tive site with bound zinc ion and comprising residues 619–
779 was modeled on trans-editing protein AlaX (PDB id
1WNU). First, multiple sequence alignment ofmAlaRS ho-
mologues retrieved from UniProt database (www.uniprot.
org) was done using Promals3D web-server. Structure ho-
mology modeling was done using SWISS-MODEL (www.
swissmodel.expasy.org). Analysis of the structures as well as
in silico mutagenesis was done using Discovery Studio 4.5
(BioVIA).
Generation of C744A and V755E mtAlaRS mice and studies
on embryos
All animal procedures were performed according to proto-
cols approved by the National Animal Experiment Board
and Regional State Administrative Agency for Southern
Finland and all experiments were done in accordance with
good practice of handling laboratory animals and of genet-
ically modified organisms.
Nucleotide changes c.2230TG>GC (p.C744A) in exon
16 of mouse Aars2 gene was introduced to generate the
C744A knock-in mice, and nucleotide change c.2264T>A
(p.V755E) in exon 17 to generate the V755E knock-in
mice. For this, BAC clones containing the mouse Aars2
gene (ENSMUSG00000023938) were obtained from BAC-
PAC Resources Center (Children’s Hospital Oakland Re-
search Institute, Oakland (CHORI), CA, USA). A 7250 bp
DNA fragment from the BAC clone, containing exons 6–
22 of Aars2 gene, was subcloned into the pACYC177 vec-
tor (New England Biolabs, MA, USA) by Red/ET recom-
bination method according to the manufacturer’s instruc-
tions (Gene Bridges GmbH, Germany). DNA fragment
containing exons 15, 16 and 17 was then amplified by PCR
and inserted into pGEM-4Z vector digested with SmaI or
ScaI restriction enzymes. In order to generate point muta-
tions in exons 16 and 17, mutagenesis was carried out by
using QuikChange Site-Directed Mutagenesis kit (Strata-
gene, CA, USA). Neomycin (Neo) resistant gene flanked
with two Frt or LoxP sites was introduced into intron 17
with FRT-PGK-gb2-Neo-FRT cassette (Gene Bridges) for
the C744A targeting construct and with LoxP-PGK-tn5-
Neo-LoxP cassette (Gene Bridges) for the V755E targeting
construct, respectively. Finally, DNA fragments containing
point mutations and the Neo cassette were excised from
pGEM-4Z with SmaI in case of C744A mutant and SmaI
and ScaI in the case of V755E mutants and replaced by us-
ing Red/ET recombination with wild type region in the pre-
viously generated pACYC177 vector containing the exons
6–22. Validity of final targeting constructs were confirmed
by restriction enzyme digestion and sequencing. All primer
sequences are available on request.
G4 embryonic stem cells (derived from 129S6/C57BL/6N
cr mouse strain) were cultured on neomycin-resistant pri-
mary embryonic fibroblast feeder layers, and 106 cells were
electroporated with 30 g of linearized targeting construct.
After electroporation, the cells were plated on 100-mm
culture dishes and exposed to G418 (300 g/ml; Sigma).
Colonies were picked after 7–9 days selection, and grown
on 96-well plates. DNA isolated from ES cell clones was
screened by long-range PCR for both 5′ and 3′ homologous
arms, and correct PCR products were further verified by se-
quencing. In order to delete the Neo cassette in the targeted
ES cells, the C744A ES cells were electroporated with plas-
mid, pCAGGS-Flpe, and V755E ES cells with pCAGGS-
Cre. After electroporation, the cells were plated on 100-
mm culture dishes and colonies were picked after cultur-
ing for 3–5 days growth, and further amplified on 96-well
plates. In order to detect targeted ES clones with Neo dele-
tion, DNAs isolated from ES cells were screened by PCR
with several different primer pairs, and the correct clones
were further confirmed by sequencing. Morula aggrega-
tion of the ES cells was carried out at the GM Mouse unit
of the Laboratory Animal Center, University of Helsinki,
according to standard protocol. The chimeric mice pro-
duced from morula aggregation were crossed to mice with
C57BL/6JOlaHsd genetic background.
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Embryo collection was done by counting the day of vagi-
nal plug as embryonic day 0.5 (E0.5). Embryos were col-
lected at E8.5 and E7.
Genotyping of the mice
Genotyping of C744A and V755E mice and em-
bryos were carried out by using primers: forward:
5′-CCTGGATCCTCGTCCTCCCTTA-3′ and reverse:
5′-TTAGAAATGTTTGCCGGTTGGG-3′. The forward
primer is located upstream of the mutation sites in the
exon 16 and the reverse primer downstream of the Frt or
the LoxP site in the intron 17 in C744A and V755E mice,
respectively. The PCR reaction results in a 401bp product
from the wild type allele, 475 bp product from the C744A
mutant allele and 497 bp product from the V755E mutant
allele.
Protein extraction, SDS-PAGE and Western blot
Protein extraction from mouse embryos, mouse embryonic
fibroblasts and inducible cells was done in RIPA buffer
(Cell signaling technology) containing proteinase inhibitor
(Thermo Fisher Scientific). Cells were incubated on ice for
10 min and embryos for 30 min. Fifteen g of protein or
the whole-embryo protein lysates were run on a 10% or
12% polyacrylamide gels (BIO-RAD) followed by semi-
dry blotting (Thermo Fisher Scientific) to a PVDF trans-
fer membrane (Merck Millipore). The membranes were
blocked in 5%milk/TBST for an hour and the immunoblot-
ting was done overnight at +4◦C with anti-AARS2 (Sigma
HPA035636), anti-COXI (Abcam ab14705), anti-GAPDH
(Cell Signaling 14C10), anti-PKM1 (Proteintech 15821–1-
AP), anti-SDHA (Abcam ab14715), anti-TOM40 (Santa
Cruz sc-11414) or anti-Rieske (Abcam ab14746) antibod-
ies. Bands were visualized with the ECL Prime Detection
Reagent (GE Healthcare), imaged with a Chemidoc XRS+
Molecular Imager (Bio-Rad) and quantified with the Im-
ageQuant TL software (GE Healthcare).
Protein extraction from mouse heart tissue was prepared
by homogenizing the tissue in PBS (100 l/10 mg of tis-
sue) with Protease Inhibitor (Halt) included. 5xRIPA was
diluted into the homogenized samples according to the PBS
volumes. Samples were incubated on ice for 20 min after
which they were centrifuged in 14 000 g for 10 min (+4◦C).
Twenty g of protein was run on 12% stain-free polyacry-
lamide gel (Bio-Rad), followed by immunoblotting using
antibodies mentioned above.
Quantitative real-time PCR (QPCR)
RNA extraction was done from freezed wild-type and
heterozygous mouse kidney samples with TRIzol (Thermo
Fisher scientific 15596–026) according to the manufac-
turer’s instructions. Homogenization of the samples was
done by using Precyllys 24 homogenizer (Bertin technolo-
gies). 1000 ng of RNA was used to generate cDNA by
Maxima First Strand cDNA Synthesis Kit for RT-qPCR
(ThermoFisher scientific K1641) according to the man-
ufacturer’s instructions. QPCR reactions were done with
DyNAmo Flash SYBR Green qPCR Kit (ThermoFisher
scientific F-415) according to the manufacturer’s instruc-
tions in CFX96TM Real-Time PCR Detection System
(Bio-Rad). 25 ng of cDNA was used in the reactions as
a template. The primers for Aars2 were following: for-
ward 5′-CTCAGCTCTGTGGGGGTTTT-3′ and reverse
5′-CCATTCGCCAGGCCTTATCT-3′ (Sigma). Rars2
gene was used as a loading control and the primers were
following forward 5′- ACACGAGTTCTTCCACCGAC-3′
and reverse 5′-ACAACATTTCCCTCCGCTGT-3′. Am-
plification conditions were: 95◦C for 7min followed by
40 cycles of 95◦C for 10 s and 60◦C for 30 s. Dissociation
curves were checked to ensure the existence of a single PCR
product and each sample was run in duplicate.
In vivo aminoacylation assay
RNA extraction was carried out from mouse skeletal mus-
cle samples with TRIzol (Thermo Fisher scientific) accord-
ing to the manufacturer’s instructions. RNA pellet was dis-
solved into 10 mM NaOAc (pH 5.2). Deacylated samples
were obtained by incubation of the RNA with equal vol-
ume of 1 M Tris–HCl (pH 9.5) at 75◦C for 15 min after
which they were put on ice. RNA (3.2 g in C744A and
controls, and 5 g in V755E mice and controls) was run to
a 6.5% polyacrylamide gel (19:1 acrylamide/bis) including
8 M urea and 0.1 M NaOAc (pH 5). Running buffer: 0.1
M NaOAc (pH 5), 2× sample buffer: 0.1 M NaOAc, 8M
Urea, 0.05 % bromophenol blue, 0.05% xylene cyanol FF.
After running the gel was blotted on to aHybond-XL nylon
membrane (GE Healthcare Amersham) in 0.5× TBE after
which the membrane was UV-crosslinked. Membrane was
prehybridized 1 h at 37◦C and hybridized overnight at 37◦C
with mitochondrial tRNAAla and tRNAArg  -32P-labeled
probes.
Culture of mouse embryonic fibroblasts
MEF cultures were prepared from E13.5 embryos. The
limbs, brain, and liver were dissected out and the rest of the
embryowas cut into small pieces with a scalpel. The embryo
pieces were put into 10 ml of 1× Trypsin–EDTA and incu-
bated for 30 min at +37◦C and vortexed every 5 min. More
trypsin (10 ml) was added and the incubation and vortexing
was continued for another 30min. Then FBS (2ml) andme-
dia (8 ml) was added and the cells centrifuged at 500 g for
5 min. The supernatant was taken out and the cell pellet
resuspended in media (20% FBS (Gibco), 1%, L-glutamate
(Lonza), 1% Penicillin Streptomycin (Lonza), 0.1 mM -
mercaptoethanol (Sigma), DMEM (Lonza)) and seeded.
Chloramphenicol and serine treatments
Wild type and heterozygous C744A MEFs were treated
with chloramphenicol (30 g/ml) (Sigma C3175) for 48 h
to inhibit mitochondrial protein translation. After that the
cells were washed twice with PBS and then grown either in
MEF-media, or inMEF-media supplemented with 10 or 20
mM of serine (Sigma S4311) for 24 h, and subjected to pro-
tein extraction for western blotting. For monitoring of cell
growth, two to three independent cell lines of wild type and
heterozygous C744A MEFs were grown in normal MEF
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Table 1. Kinetic parameters of hmtAlaRS for Ala and Ser in ATP-PPi exchange reactiona
Amino acid kcat (s−1) Km (mM) kcat /Km (s−1 mM−1) Discrimination factor (DF)b
Ala 4.65 ± 0.21 5.68 ± 0.18 0.82 1
Ser 0.74 ± 0.04 515 ± 50 1.44E-03 569
aThe results are the average of three independent repeats with standard deviations indicated.
bDF is calculated by equation the DF = (kcat/Km)Ala/(kcat/Km)Ser
media, orwith 40mMof added serine, and the cell prolifera-
tion was followed for over 40 h using the Cell IQ (Chip-man
technologies).
Histochemistry
For hematoxylin eosin stainings mouse cerebellums were
embedded in paraffin and cut into 5 m tissue slides. For si-
multaneous cytochrome c oxidase (COX) and succinate de-
hydrogenase (SDH) activity stainings, skeletal muscle sam-
ples were covered with fixative (Sakura) and snap frozen
in isopentane/liquid nitrogen, and cut into 7 m thick
cryoslides.
Statistical analysis
All numerical data are expressed as mean± SEM. Student’s
t-test was used for statistical analysis.
RESULTS
AlaRSs are highly conserved enzymes containing separate
domains for aminoacylation and editing, and a C-terminal
domain (Figure 1A). For example, the sequence similar-
ity for the editing domains of human mitochondrial and
archeon A. fulgidus AlaRSs, for which a full crystal struc-
ture is available (30), is 39.8% (23). However, biochemical
studies using the recombinant mtAlaRS have neither been
previously reported, nor the functionality of the editing do-
main of mtAlaRS demonstrated. We obtained the recombi-
nant human mature mtAlaRS (Ser26-Leu987) (hmtAlaRS),
excluding theN-terminalmitochondrial targeting sequence,
from overexpression inE. coli (25). The requirement of edit-
ing by an ARS is generally judged from the discrimina-
tion efficiency toward cognate and noncognate amino acids.
Therefore, we first measured the kinetic parameters of hm-
tAlaRS for alanine and serine in ATP-PPi exchange reac-
tion. HmtAlaRS misactivated Ser with a discriminator fac-
tor of 1/569 (Table 1), which is significantly larger than
1/3300, the proposed threshold for frequency of errors in
protein synthesis (31), suggesting that mtAlaRS requires
editing function to prevent Ala-to-Ser misincorporation in
mitochondria.
Next, we tested the effects of two editing domain muta-
tions on the aminoacylation and editing functions of mtA-
laRS in vitro. The first hmtAlaRS substitution C749A is
equivalent to the editing-deficient E. coli mutant C666A
(16), and to the embryonic lethal C723A in the mouse
cytosolic AlaRS (13). This cysteine is fully conserved in
AlaRSs, and is critical for zinc binding in the editing ac-
tive site and thus for the deacylation reaction (Figure 1A).
Structural prediction suggests that its substitution for ala-
nine severely disrupts the editing activity (Figure 1B). The
second hmtAlaRSmutant V760Emimics the stimouse mu-
tation A734E (13). Only hydrophobic amino acids (alanine,
valine, leucine, isoleucine and methionine) are tolerated at
this position (Figure 1A). This is a structural residue sup-
porting the architecture of the editing site and forming hy-
drophobic interactions with conserved alanine, leucine and
valine (mouse A629, L632 and V683, Figure 1B). Mutation
for glutamic acid is predicted to affect the coordination of
zinc ion by the conserved histidine (mouseH748, Figure 1B)
resulting in a decreased deacylation rate as demonstrated
for the stimutation (13). In the ATP-PPi exchange reaction
both hmtAlaRS mutants C749A and V760E exhibited sim-
ilar alanine activation activity as the wild type hmtAlaRS
(Figure 1C). In vitro aminoacylation assay indicated that
the mutants C749A and V760E displayed only slightly de-
creased tRNAAla charging activity compared with wild type
mtAlaRS (Figure 1D). Determination of post-transfer edit-
ing ofmischarged Ser-tRNAAla showed that the C749Amu-
tant was severely defective in editing while the initial veloc-
ity of the post-transfer editing activity of the V760Emutant
was only slightly reduced (Figure 1E and F). In vitro mis-
aminoacylation assay demonstrated that the C749Amutant
generated considerably more Ser-tRNAAla than the wild
type synthetase, consistent with its abolished post-transfer
editing activity (Figure 1G). The V760E mutant produced
less Ser-tRNAAla than the severe mutant, but also more
than the wild type enzyme. These results indicate that while
the twomtAlaRS editing domainmutants had a nearly nor-
mal aminoacylation activity, they both displayed deficiency
in editing, albeit at different severities (C749Awas more de-
fective in editing than V760E).
To investigate the in vivo importance of editing by
mtAlaRS in mammalian mitochondria, we generated two
knock-in mouse models of mtAlaRS with amino acid
changes corresponding to the mild and severe editing
mutants described above. The mouse mtAlaRS is en-
coded by the nuclear gene Aars2 (Figure 1A), and the in-
troduced codon changing mutations were the following:
c.2230TG>GC (p.C744A) and c.2264T>A (p.V755E) in
exons 16 or 17, respectively (Figure 2A and D). Following
morula aggregation of targeted ES cells, the chimeras were
bred to C57BL/6JOlaHsd females. Crossing of heterozy-
gous littermates failed to result in Mendelian proportions
of genotypes as no homozygous C744A or V755E knock-
in mice were obtained (Figure 2B). Investigation of embry-
onic development in either of the knock-in mouse strains
revealed that the homozygous embryos were significantly
smaller at embryonic day 8.5 (E8.5) than their wild type
or heterozygous littermates, indicating that both mutations
are embryonic lethal in the homozygous state (Figure 2C).
Genotyping and sequencing confirmed the small underde-
veloped embryos at E7 to be homozygous mutants, while
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Figure 1. The mitochondrial alanyl-tRNA synthetase has a functional editing domain. (A) The human/mouse AARS2/Aars2 gene, coding for mitochon-
drial alanyl-tRNA synthetase (mtAlaRS), is composed of 22 exons. Exons 1–11 code for the aminoacylation domain, exons 12–20 for the editing domain
and exons 20–22 for the C-terminal domain. Amino acid sequence alignment is shown for a part of the editing core of AlaRS in E. coli and mouse, and
mtAlaRS in several vertebrate species. In the alignment, green colour indicates fully conserved amino acids, and red and blue colour indicate the mutated
amino acids. (B) Structural predictions for the mutations in the editing core are shown for mouse mtAlaRS. Cysteine 744 (pink) is critical for zinc binding
(purple) in the editing active site as shown in the upper left figure. Substitution of cysteine 744 for alanine is predicted to severely disrupt the zinc binding
and thus the editing activity of mtAlaRS as shown in the bottom left figure. Valine 755 supports the architecture of the editing site as shown in the upper
right figure. Its change for glutamic acid affects the position of histidine 748, one of zinc binding ligands, due to repulsion forces between glutamic acid
755, alanine 629, leucine 632 and valine 683 as shown in the bottom right figure. (C) Alanine activation of the wild type hmtAlaRS and the C749A and
V760E mutants in ATP-PPi exchange reaction. (D) Alanine charging of tRNAAla by the wild type hmtAlaRS and the C749A and V760E mutants in in
vitro aminoacylation assay. (E) A representative TLC showing hydrolysis of Ser-[32P]tRNAAla by hmtAlaRS, and the mutants C749A and V760E. Nu-
clease S1-generated Ser-[32P]AMP (reflecting Ser-[32P]tRNAAla) and [32P]AMP (reflecting free [32P]tRNAAla) were separated by TLC. A control reaction
represented the spontaneous hydrolysis of Ser-[32P]tRNAAla without the addition of enzyme. (F) Graph of the post-transfer editing of Ser-[32P]tRNAAla
by wild type hmtAlaRS and the C749A and V760E mutants. (G) Mis-aminoacylation of wild type hmtAlaRS and the C749A and V760E mutants with
serine. In all graphs mean values with error bars indicating SD are shown.
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Figure 2. Editing-deficient knock-inmousemodels ofmtAlaRS are early embryonic lethal. (A) Targeting strategies forC744AandV755Eknock-inmutants
in mice. The mutations were introduced into exons 16 or 17 by homologous recombination. The Neo cassette that was used for clone selection was excised
by Flp or Cre recombination from the ES cells. (B) Weaned 3-week-old pups and their genotypes from heterozygote parental crossings. WT, wild type. (C)
Images of mouse embryos of different genotypes at E8.5. (D) Sequencing traces of the mutation sites from mouse embryos at E8.5. (E) Western blot of
cytochrome c oxidase subunit I (COXI), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and PKM1 pyruvate kinase (PKM1), and a genotyping
of E7 embryos.
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proteins in them had mostly been degraded, preventing fur-
ther investigation of these embryos (Figure 2D and E).
The viability of mouse embryonic fibroblasts (MEFs) ho-
mozygous for the sti mutation was reported to be sensi-
tive to serine supplemented to the culture medium. Further-
more, heterozygous stiMEFs were shown to have interme-
diate serine sensitivity in comparison to the wild type and
homozygous cells (13). We were unable to culture MEFs
of the small homozygous C744A or V755E mtAlaRS em-
bryos, but we prepared wild type and heterozygous MEFs.
The heterozygous MEFs of either mouse line showed an
amount of mtAlaRS protein comparable to the wild type
cells (Figure 3A), suggesting that the editing-mutant syn-
thetases were stable. Tissues from heterozygous animals
showed no compensatory increase in Aars2 mRNA lev-
els, further supporting the stability and functionality of the
mutated enzymes (Figure 3B). Furthermore, the levels of
aminoacylated mt-tRNAAla were not substantially altered
in muscle of heterozygotes of either mouse line in compari-
son to wild type littermates, showing that the editing muta-
tions did not result in reduced tRNA charging or stability
(Figure 3C).We then cultured theMEFs in normal medium
or in medium with 40 mM of serine, and followed their pro-
liferation for over 40 h. Increased serine reduced cell pro-
liferation of both wild type and heterozygous MEFs, but
no differences were observed between the genotypes (Fig-
ure 3D). To test the effects of supplemented serine on mi-
tochondrial protein synthesis, we pretreated wild type and
heterozygous C744A MEFs with chloramphenicol, which
blocks the translation elongation step on the mitoribosome,
for 48 h to deplete the cells of mtDNA-encoded respira-
tory chain subunits. Next, the cells were grown in normal
medium or with 10 or 20 mM of supplemented serine for 24
h and monitored for the recovery of the respiratory chain
subunit COXI of Complex IV by Western blot. Following
the serine supplementation, the recovery of COXI protein
levels was found to be comparable in wild type and het-
erozygous cells (Figure 3E). These results indicate that in
the presence of the wild type enzyme, the expression of
editing-deficient synthetase is not sufficient to induce no-
ticeable damage to synthesized mitochondrial proteins even
with increased concentrations of serine.
While the editing-deficient cytoplasmic C723A AlaRS
mutation was found to be embryonic lethal in homozygous
mice, even the heterozygousmice presented with amild phe-
notype of cerebellar neuron loss at one year of age (13). We
therefore followed the heterozygous C744A mtAlaRS mice
by monitoring their weights and appearance regularly and
sampled the tissues at one year of age. No differences in
weight gain or behavior were observed during the one year
follow-up between the different groups of mice (Figure 4A).
The heart to body weight ratios of the sacrificed mice were
also comparable (Figure 4B).We stained the skeletal muscle
of the 1-year-old mice for the activity of COX, the respira-
tory chain Complex IV, and found it to be normal in het-
erozygous C744A mice (Figure 4C). COXI protein levels in
the heart tissue were also normal as detected bywestern blot
(Figure 4D). The cerebellums of the heterozygous C744A
mice also appeared normal and no neuron loss or lack of
COX activity was observed (Figure 4E, and not shown).
These results further illustrate that heterozygosity for a se-
vere mtAlaRS editing defect is not pathogenic.
DISCUSSION
The significance of editing mischarged tRNAs in mam-
malian cytoplasm has been undoubtedly demonstrated by
the embryonic lethal phenotype of AlaRSmice carrying the
severe editing mutation C723A (17), and by the progressive
neurodegeneration phenotype of the milder editing muta-
tion in sti mice (13). The severe cytoplasmic mutant was
shown to increase mischarging 15-fold in vitro, whereas the
stimutation led to a two-fold increase. However, the impor-
tance of tRNA proofreading has not been clear in mam-
malian mitochondria. We show here that the hmtAlaRS
is capable of editing mischarged tRNAAla in vitro. We fur-
ther identify a severe editing domain mutation of mtAlaRS
that prevents the post-transfer editing of mischarged Ser-
tRNAAla, while another mutation displays a milder editing
defect. Finally, we show that both of these editing mutants,
mild and severe, result in early embryonic lethality in mice,
demonstrating that the editing function of an aminoacyl-
tRNA synthetase is essential in mammalian mitochondria.
Mitoribosomes are specialized machines for the synthe-
sis of only 13 polypeptides that are essential subunits of
the oxidative phosphorylation system. These proteins are
highly hydrophobic, which requires them to be directly syn-
thesized into the mitochondrial inner membrane. We have
previously shown that misincorporation of an arginine ana-
log, canavanine, during mitochondrial translation causes
mitoribosome stalling when the nascent polypeptide con-
taining the analog is unable to fold properly (32). The mis-
folding rapidly decreases the stability of the newly synthe-
sized proteins that cannot be correctly inserted into mem-
brane, leading to reduction in the amounts of fully assem-
bled respiratory chain complexes (32). Similar severe out-
comes could be expected when alanines in mitochondrial
proteins are replaced by serines due to mischarging of tR-
NAs, thus leading to embryonic lethality in mice. However,
it was unexpected that the editing defect causing moderate
misincorporation and only a cerebellar phenotype in the cy-
toplasmic AlaRS mice (13), was also embryonic lethal in
mtAlaRS mice. Based on this result, it could be speculated
that mitochondrial protein synthesis is highly sensitive to
serine misincorporation. Interestingly, both mtARSs that
now have been demonstrated to have a functional editing
domain, mtAlaRS (this study) and mtThrRS (22), edit ser-
ine. Recent study measuring metabolites and amino acid
levels in themitochondrialmatrix ofHeLa cells showed that
while alanine levels were high within mitochondria, the ser-
ine levels were negligible (33), suggesting that low serine lev-
elsmay be important tomaintain to complement the editing
activities of mtAlaRSs in preventing the toxic serine mis-
translation. However, the serine concentration in rat liver
was found to be greater in an earlier study (34) in which
case active editing by mtAlaRS would be highly necessary,
which is supported by our findings.
The phenotype of the sti mutant mice being restricted to
the cerebellum and having a relatively slow progression as
the mice were still alive at one year of age (13) suggested
that the milder editing defect of the cytoplasmic synthetase
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Figure 3. Wild type mtAlaRS compensates for the editing-mutant synthetase in heterozygous animals and cells. (A) Western blot analysis of the mtAlaRS
protein levels in wild type (WT) and heterozygous C744A or V755E mouse embryonic fibroblasts (MEFs). GAPDH is shown as the loading control. (B)
QPCR analysis of the Aars2 mRNA levels in WT (n = 3) and heterozygous C744A or V755E (n = 3) kidney samples. (C) Mt-tRNA-Ala aminoacylation
in WT and heterozygous C744A or V755E mouse skeletal muscle total RNA extracts. DA denotes a deacylated sample. (D) Proliferation of WT (n = 2)
and heterozygous C744A or V755E (n = 3) MEF lines in normal media or in media with supplemented serine. (E) Representative Western blot for COXI
and quantification of three individual blots of wild type and heterozygous C744A MEFs after 48 h of chloramphenicol (CAP) treatment, followed by a
24 h recovery in normal media or in media with increased concentration of serine (10 or 20 mM). CAP was used to deplete proteins synthesized by the
mitoribosomes. In all graphs mean values with error bars indicating SEM are shown.
Downloaded from https://academic.oup.com/nar/article-abstract/46/2/849/4708262
by St George's University of London user
on 31 January 2018
858 Nucleic Acids Research, 2018, Vol. 46, No. 2
Figure 4. Normal development of the heterozygous C744Amice. (A) Weight gain of wild type (WT) and heterozygous C744Amales (M) and females (F) (n
= 5/group). (B) Heart/body weight ratio of the one-year-old mice (n = 5/group). (C) COX/SDH staining of the skeletal muscle of the one-year-old mice.
(D) Western blot analysis of mitochondrial proteins in heart tissue protein extracts of the one-year-old mice. (E) Hematoxylin eosin staining of cerebellar
sections of the one-year old mice. In the graph mean values with error bars indicating SEM are shown.
was tolerated in cell types other than the vulnerable Purk-
inje neurons. One possibility is that protective mechanisms
that prevent serine misincorporation are present in other
cell or tissue types but not in the cerebellar neurons. AlaXps,
the free-standing editing domain homologs of AlaRSs, are
found throughout evolution, and are thought to provide
functional redundancy for the universal toxicity of mis-
translating serine for alanine (14,35,36). Mammalian cells
suppressed for AlaXp expression led to a serine-sensitive in-
crease in the accumulation of misfolded proteins (37). The
suppressive role of the mammalian AlaXp, which is found
in the cytoplasm but not in mitochondria (37), may con-
tribute to the difference between the phenotypes caused by
the moderate editing defect in the two cellular compart-
ments.
Numerous examples have shown that loss of any gene es-
sential for mitochondrial gene expression results in lethal-
ity of mouse embryos around E8.5 (38). Of the mtARSs,
this phenotype has been demonstrated for mtAspRS by
Dars2 knockout mouse (39). This suggests that the embry-
onal phenotype of the editing-deficient mtAlaRS mice does
not differ from what is expected for a knockout of Aars2,
completely lacking aminoacylation activity. Owing to the
early death of the homozygous editing-mutant embryos, we
were not able to address the stability of the mutant mtA-
laRS proteins in vivo and their effect on aminoacylation. In
heterozygous animals and MEFs the mtAlaRS protein lev-
els were normal, without signs of compensatory increase,
and the aminoacylation of tRNAAla was comparable towild
type littermates, suggesting that the lethality of the homozy-
gotes was not caused by loss of aminoacylation activity.
Also the in vitro stability of the mutant proteins supports
that the phenotypes were not due to protein instability. In
vitro, the aminoacylation activity of the editing-mutant en-
zymes was slightly lower in comparison to the wild type
synthetase. However, healthy parents of some of the pa-
tients with pathogenic AARS2 mutations carry total loss
of function alleles on one chromosome (23), indicating that
even a 50% reduction in aminoacylation activity is suffi-
cient for mitochondrial protein synthesis. Our results thus
support that tRNAmischarging and the subsequent amino
acid misincorporation was the cause of embryonal lethality
in our mice. Unfortunately, the lack of viable homozygous
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mice preventedmore detailed studies of the consequences of
amino acid misincorporation into mitochondrial proteins.
TheAARS2 gene encodingmtAlaRS has been associated
with two disease phenotypes in human patients. Firstly, a
recessive European founder mutation was found to cause
early-onset lethal cardiomyopathy (23,24), and secondly,
other recessive mutations were identified in patients with
leukodystrophy and ovarian failure (40). The cardiomyopa-
thymutation locates to the editing domain ofmtAlaRS, and
was speculated to cause mistranslation. Intriguing, among
the highly tissue-specific mtARS diseases, the mtAlaRS de-
fect is the only one causing cardiomyopathy, which could
suggest editing defect as a different mechanism from the
other mitochondrial synthetase diseases. We have, however,
previously shown that unlike the editing mutants modeled
in mice in this study, the mutation causing cardiomyopathy
is not located in the editing core of mtAlaRS. Rather, we
predicted the mutation to have an effect on aminoacylation
as part of the editing domain’s contribution to tRNA bind-
ing (23,41). No human patient phenotypes have thus been
described with mutations affecting the editing function of
a mitochondrial synthetase. The results of this study sug-
gest that such a mutation in recessive form would prevent
embryonic development.
Our heterozygous mtAlaRS mice were completely nor-
mal, even for the duration of the one year follow-up of the
severely editing-deficient C744Amice, and the heterozygous
MEFs from those mice did not show a proliferation defect
or a problem of synthesizing COXI even when stressed with
increased concentrations of serine. The nearly normal phe-
notype of the heterozygous C723A AlaRS mice was sug-
gested to indicate that the wild-type AlaRS was sufficient
in trans to hydrolyze the Ser-tRNAAla generated by the mu-
tant enzyme, and the trans-editing was indeed shown to oc-
cur in vitro (17). Based on the proposed ability of AlaRS
to trans-edit mischarged tRNAs, our results suggest that
trans-editing by the wild type synthetase is fully sufficient
to prevent mistranslation in mitochondria of the heterozy-
gous mtAlaRS mice.
Our study demonstrates that the editing function of mtA-
laRS is essential for mouse development. Therefore, in mi-
tochondria a high translation fidelity is required and other
protein quality mechanisms are not able to overcome the
damage caused by amino acid misincorporation. Thus, it is
not clear why most mitochondrial synthetases do not have
an editing function in place. One explanation for this could
be that some mtARSs have achieved fidelity by incorporat-
ing a more specific synthetic active site that is not prone
to errors (21,42). We suggest that mammalian mitochon-
dria require a strict amino acid specificity, which is achieved
by differently evolved properties of aminoacyl-tRNA syn-
thetases and complemented by other protein quality control
systems. Furthermore, the toxicity of serine misincorpora-
tion may be a particularly important problem in mitochon-
dria.
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